Borah Bijan J, Yao Xiaoxi, Laughlin-Tommaso Shannon K, Heien Herbert C, Stewart Elizabeth A
Departments of Health Sciences Research, Obstetrics and Gynecology, and Surgery and the Kern Center for Science of Health Care Delivery, Mayo Clinic, and the Departments of Obstetrics-Gynecology and Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota.
Obstet Gynecol. 2017 Nov;130(5):1047-1056. doi: 10.1097/AOG.0000000000002331.
To compare risk of reintervention, long-term clinical outcomes, and health care utilization among women who have bulk symptoms from leiomyoma and who underwent the following procedures: hysterectomy, myomectomy, uterine artery embolization, and magnetic resonance-guided, focused ultrasound surgery.
This was a retrospective analysis of administrative claims from a large U.S. commercial insurance database. Women aged 18-54 years undergoing any of the previously mentioned leiomyoma procedures between 2000 and 2013 were included. We assessed the following outcome measures: risk of reintervention between uterine-sparing procedures, risk of other surgical procedures or complications of the index procedure, 5-year health care utilization, pregnancy rates, and reproductive outcomes. Propensity score matching along with Cox proportional hazard models were used to adjust for differences in baseline characteristics between study cohorts.
Among the 135,522 study-eligible women with mean follow-up of 3.4 years, hysterectomy was the most common first-line procedural therapy (111,324 [82.2%]) followed by myomectomy (19,965 [14.7%]), uterine artery embolization (4,186 [3.1%]) and magnetic resonance-guided focused ultrasound surgery (47 [0.0003%]). Small but statistically significant differences were noted for uterine artery embolization and myomectomy in reintervention rate (17.1% compared with 15.0%, P=.02), subsequent hysterectomy rates (13.2% compared with 11.1%, P<.01) and subsequent complications from index procedures (18.1% compared with 24.6%, P<.001). During follow-up, women undergoing myomectomy had lower leiomyoma-related health care utilization, but had higher all-cause outpatient services. Pregnancy rates were 7.5% and 2.2% among myomectomy and uterine artery embolization cohorts, respectively (P<.001) with both cohorts having similar rates of adverse reproductive outcome (69.4%).
Although the overwhelming majority of women having leiomyoma with bulk symptoms underwent hysterectomy as their first treatment procedure, among those undergoing uterine-sparing index procedures, approximately one seventh had a reintervention, and one tenth ended up undergoing hysterectomy during follow-up. Compared with women undergoing myomectomy, women undergoing uterine artery embolization had a higher risk of reintervention, lower risk of subsequent complications, but similar rate of adverse reproductive outcomes.
比较有子宫肌瘤相关症状且接受了以下手术的女性再次干预的风险、长期临床结局及医疗保健利用情况:子宫切除术、肌瘤切除术、子宫动脉栓塞术以及磁共振引导聚焦超声手术。
这是一项对美国大型商业保险数据库中的管理索赔进行的回顾性分析。纳入了2000年至2013年间接受上述任何一种子宫肌瘤手术的18 - 54岁女性。我们评估了以下结局指标:保留子宫手术之间再次干预的风险、首次手术的其他手术或并发症风险、5年医疗保健利用情况、妊娠率及生殖结局。使用倾向评分匹配法以及Cox比例风险模型来调整研究队列之间基线特征的差异。
在135,522名符合研究条件且平均随访3.4年的女性中,子宫切除术是最常见的一线手术治疗方式(111,324例[82.2%]),其次是肌瘤切除术(19,965例[14.7%])、子宫动脉栓塞术(4,186例[3.1%])和磁共振引导聚焦超声手术(47例[0.0003%])。子宫动脉栓塞术和肌瘤切除术在再次干预率(分别为17.1%和15.0%,P = 0.02)、后续子宫切除术率(分别为13.2%和11.1%,P < 0.01)以及首次手术后续并发症发生率(分别为18.1%和24.6%,P < 0.001)方面存在虽小但具有统计学意义的差异。在随访期间,接受肌瘤切除术的女性子宫肌瘤相关医疗保健利用较低,但全因门诊服务较高。肌瘤切除术组和子宫动脉栓塞术组的妊娠率分别为7.5%和2.2%(P < 0.001),两组不良生殖结局发生率相似(69.4%)。
虽然绝大多数有子宫肌瘤相关症状的女性首次治疗选择子宫切除术,但在接受保留子宫的首次手术的女性中,约七分之一有再次干预情况,十分之一在随访期间最终接受了子宫切除术。与接受肌瘤切除术的女性相比,接受子宫动脉栓塞术的女性再次干预风险更高,后续并发症风险更低,但不良生殖结局发生率相似。